A Study to Compare Medications in Patients with Advanced Parkinson's Disease

Neurological
Official Title A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

Purpose

The purpose of this study is to find out how well ABBV-951 works to control Parkinson's disease symptoms compared to oral Carbidopa (CD)/Levodopa (LD). The study is also seeking to test whether ABBV-951 is well tolerated in patients with Parkinson's disease.

Could this study be right for you?

  1. Male or female, age 30 or older
  2. Has not received deep brain stimulation, Carbidopa (CD)/Levodopa (LD) enteral suspension, or any other Parkinson's Disease (PD) medication as continuous daily infusion
  3. Subject does not have a history of significant skin conditions or disorders
  4. Subject does not have a recent (within 6 months before screening) history of drug or alcohol abuse
  5. Subject does not have a history or presence of psychotic episodes
  6. Subject does not have other clinically significant unstable medical conditions
  7. Subject must have a diagnosis of levodopa-responsive idiopathic PD

* other eligibility criteria to be discussed/reviewed with the study team

Age Range

30 and up